Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
A Teva plant in Israel. Photo: Menahem Kahana/AFP via Getty Images
Several companies that manufacture generic drugs are talking with the Department of Justice to avoid indictments for allegedly colluding to raise their prices. They would pay fines and admit that some allegations are true, Bloomberg reports.
The big picture: These potential "deferred prosecution agreements" would only cover the federal probe, not the state-led antitrust investigation, but it could shed light on any price fixing that occurred in the generic drug marketplace.